NEW YORK, April 04, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Huntsman Corporation, Pfizer Inc, Chesapeake Energy Corporation.
Huntsman Corporation (NYSE:HUN) shares increased 4.88% to $18.28. The company, on Mar. 21, announced a combined investment of $135 million at two of its worldscale methylene diphenyl diisocyanate (MDI) manufacturing facilities: increasing capacity at its Geismar, USA site and upgrading its downstream specialties production capability at its Rotterdam, the Netherlands site.
Is HUN a Strong Buy After Today’s Gap Up? Let’s Find Out Here http://bestdarnpennystocks.com/landing/home-aw.php?code=HUN (OR Just copy and paste the link)
Additionally, the company announced that it will hold its 2013 annual meeting of stockholders on Thursday, May 2, 2013 at 8:30 a.m., local time, at The Four Seasons Hotel, 1300 Lamar Street, Houston, Texas 77010. Holders of record as of the close of business on March 8, 2013 will be entitled to vote at the meeting.
Chesapeake Energy Corporation(NYSE:CHK) shares fell 0.31% to $19.12. Gastar Exploration Ltd. on Apr. 1 announced a wide-ranging agreement to expand its oil acreage and help settle all of its litigation with Chesapeake Energy Corp. Gastar said it has entered into a definitive agreement to buy proven reserves and undeveloped leasehold interests in Kingfisher and Canadian counties, Oklahoma from Chesapeake Energy.How Should Investors Trade CHK After The Recent Slump? Get Free Trend Analysis Here http://bestdarnpennystocks.com/landing/home-aw.php?code=CHK (OR Just copy and paste the link)
Additionally, the company, on April. 1, announced that its Board of Directors has established a three-person Office of the Chairman while continuing its previously announced CEO search process with the assistance of Heidrick & Struggles.
A federal appeals court has directed Pfizer Inc.(NYSE:PFE) to pay about $142 million for marketing and prescribing of epilepsy drug Neurontin for unapproved uses.
A panel of appellate judges refused to overturn a ruling in favor of Kaiser Foundation Health Plan, which claimed it had been damaged after prescribing Neurontin for conditions it did not effectively treat, on fraudulent marketing by Pfizer.
The panel has also revived similar claims from insurer Aetna and class action allegations from Harden Manufacturing Corp.
Is PFE a Buy At New highs? Get Free Report Here http://bestdarnpennystocks.com/landing/home-aw.php?code=PFE (OR Just copy and paste the link)
The ruling in the Kaiser case upholds a lower court's decision not to allow a new trial after a jury had awarded the drug-maker $142 million. Pfizer had marketed Neurontin for bipolar disorder, migraines and neuropathic pain, none of which had been approved by the FDA.Kaiser said it was "very pleased" and that "justice has been achieved for our members and the physicians, pharmacists and staff who care for them." David Frederick, an attorney for Kaiser, said he was "gratified by the court's carefully crafted decision."
Pfizer expressed its dissatisfaction saying that it believes "there was no basis in fact or law" for the award. In the Aetna and Harden cases, Pfizer thought that the lower court's dismissals had been fair."We are exploring our appellate options in all three of these cases," the company said. Pfizer's attorneys could not be reached.
About bestdarnpennystocks.combestdarnpennystocks.com’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
DisclaimerThe assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.Contacts:bestdarnpennystocks.com 1419 Westwood Blvd Los Angeles, CA90024email@example.com